術後部分胃切除患者におけるエボロクマブ誘発性アレルギー反応:症例報告
Xuxi Hong1, Xuehui Jiang2, Xiaohui Xu3
1Department of Cardiology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.
Rationale:
Evolocumab, a novel proprotein convertase subtilisin/kexin type 9 inhibitor, is widely used for intensive lipid-lowering therapy. However, its safety profile in patients with altered gastrointestinal anatomy (e.g., partial gastrectomy) remains inadequately characterized, particularly regarding allergic risks linked to immune microenvironment changes.
Patient Concerns:
A 55-year-old male with coronary artery disease and a history of partial gastrectomy received subcutaneous evolocumab (140 mg) post-percutaneous coronary intervention. Within 24 hours, he developed a diffuse erythematous rash with pruritus on the chest and back.
Diagnoses:
Coronary artery disease (status post-percutaneous coronary intervention); allergic rash induced by evolocumab (Naranjo score: 7, WHO-UMC causality: probable).
Interventions:
Evolocumab was discontinued. Intravenous dexamethasone (5 mg/day) and oral cetirizine (10 mg/day) were administered for allergy control.
Outcomes:
Rash and pruritus significantly improved within 48 hours. One-week follow-up confirmed full resolution without hyperpigmentation.
Lessons:
Post-gastrectomy patients may face heightened evolocumab allergy risks due to immune dysregulation. Pre-administration assessment of surgical history and close post-dose monitoring are critical.
関連する概念動画
Allergic Reactions
Allergic Drug Reactions
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
Drug Toxicity: Allergic Reactions
Allergic Reactions: Anaphylaxis
Peptic Ulcer Disease III: Clinical Manifestations and Complications

